Literature DB >> 18365993

Pulmonary zygomycosis.

Vasilios Pyrgos1, Shmuel Shoham, Thomas J Walsh.   

Abstract

Zygomycosis has emerged as an increasingly common infection in immunocompromised patients. Although the majority of these cases are community acquired, hospital outbreaks have been described, linked to the use of contaminated products. Risk factors for development of zygomycosis include uncontrolled diabetes mellitus, neutropenia, use of immunosuppressive medications, and iron overload states. Recent studies have shown the central role of iron in the pathogenesis of zygomycosis and the effect of disease states such as ketoacidosis and hyperglycemia on the availability of iron to the Zygomycetes. These organisms most commonly infect the sinuses, lungs, central nervous system, and skin and soft tissues. Diagnosis often involves invasive procedures, including deep tissue biopsy, because radiological studies are not specific for this disease, and other less invasive diagnostic modalities have not yet been proven to be sensitive or specific. Treatment may require a combined medical and surgical approach in these frequently frail patients; yet, even with such aggressive measures the mortality of zygomycosis remains high.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18365993     DOI: 10.1055/s-2008-1063850

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  8 in total

1.  Development of new strategies for early diagnosis of mucormycosis from bench to bedside.

Authors:  Thomas J Walsh; Anna Skiada; Oliver A Cornely; Emmanuel Roilides; Ashraf Ibrahim; Theoklis Zaoutis; Andreas Groll; Olivier Lortholary; Dimitrios P Kontoyiannis; George Petrikkos
Journal:  Mycoses       Date:  2014-12       Impact factor: 4.377

2.  Mucor circinelloides as a cause of invasive maxillofacial zygomycosis: an emerging dimorphic pathogen with reduced susceptibility to posaconazole.

Authors:  Zia U Khan; Suhail Ahmad; Arnost Brazda; Rachel Chandy
Journal:  J Clin Microbiol       Date:  2009-01-26       Impact factor: 5.948

3.  Pharmacokinetics of liposomal amphotericin B in pleural fluid.

Authors:  Brad Moriyama; Parizad Torabi-Parizi; Alexandra K Pratt; Stacey A Henning; Gennethel Pennick; Yvonne R Shea; Sinchita Roy Chowdhuri; Michael G Rinaldi; A John Barrett; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

4.  A clinicopathological study of pulmonary mucormycosis in cancer patients: extensive angioinvasion but limited inflammatory response.

Authors:  Ronen Ben-Ami; Mario Luna; Russell E Lewis; Thomas J Walsh; Dimitrios P Kontoyiannis
Journal:  J Infect       Date:  2009-06-11       Impact factor: 6.072

5.  Antifungal activity of colistin against mucorales species in vitro and in a murine model of Rhizopus oryzae pulmonary infection.

Authors:  Ronen Ben-Ami; Russell E Lewis; Jeffrey Tarrand; Konstantinos Leventakos; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2009-10-26       Impact factor: 5.191

Review 6.  Mucormycosis: risk factors, diagnosis, treatments, and challenges during COVID-19 pandemic.

Authors:  Ayushi Sharma; Anjana Goel
Journal:  Folia Microbiol (Praha)       Date:  2022-02-26       Impact factor: 2.629

7.  Targeted Delivery of Antifungal Liposomes to Rhizopus delemar.

Authors:  Quanita J Choudhury; Suresh Ambati; Zachary A Lewis; Richard B Meagher
Journal:  J Fungi (Basel)       Date:  2022-03-30

8.  Rhizopus microsporus lung infection in an immunocompetent patient successfully treated with amphotericin B: A case report.

Authors:  Long Chen; Yuan Su; Xian-Zhi Xiong
Journal:  World J Clin Cases       Date:  2021-12-16       Impact factor: 1.337

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.